

# Hutchison Whampoa Limited

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 013)**

## **OVERSEAS REGULATORY ANNOUNCEMENT**

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 71.6% owned subsidiary of Hutchison Whampoa Limited.

As at the date of the announcement, the Directors of Hutchison Whampoa Limited are:

**Executive Directors:**

Mr. LI Ka-shing (*Chairman*)  
Mr. LI Tzar Kuoi, Victor (*Deputy Chairman*)  
Mr. FOK Kin-ning, Canning  
Mrs. CHOW WOO Mo Fong, Susan  
Mr. Frank John SIXT  
Mr. LAI Kai Ming, Dominic  
Mr. KAM Hing Lam

**Non-executive Directors:**

Mr. George Colin MAGNUS  
Mr. William SHURNIAK

**Independent Non-executive Directors:**

The Hon. Sir Michael David KADOORIE  
Mr. Holger KLUGE  
Mr. William Elkin MOCATTA  
*(Alternate to The Hon. Sir Michael  
David Kadoorie)*  
Mr. Simon MURRAY  
Mr. OR Ching Fai, Raymond  
Mr. WONG Chung Hin  
*(also Alternate to Mr. Simon Murray)*

Hong Kong, 2 April 2007



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited  
(AIM: HCM)**

**Board Change**

**London: Monday, 2 April 2007:** The Board of Hutchison China MediTech Limited ("Chi-Med") today announces that Mr. Stephen Yeung who has been a Non-executive Director of Chi-Med since April 2006 retired with effect from 1 April 2007.

Simon To, Chairman said: "We would like to express our deep appreciation for all his contribution to Chi-Med and wish him well."

Stephen Yeung was appointed to the Chi-Med Board last year as a representative of Hutchison Whampoa Limited's interests.

**Ends**

**Enquiries**

**Chi-Med** Telephone: +852 2121 8200

Christian Hogg, CEO

**Citigate Dewe Rogerson** Telephone: +44 (0) 20 7638 9571

Anthony Carlisle +44 (0) 7973 611 888

Yvonne Alexander +44 (0) 7866 610 682

**About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.